A large-area organic transistor with 3D-printed sensing gate for noninvasive single-molecule detection of pancreatic mucinous cyst markers
Early diagnosis in a premalignant (or pre-invasive) state represents the only chance for cure in neoplastic diseases such as pancreatic-biliary cancer, which are otherwise detected at later stages and can only be treated using palliative approaches, with no hope for a cure. Screening methods for the purpose of secondary prevention are not yet available for these cancers. Current diagnostic methods mostly rely on imaging techniques and conventional cytopathology, but they do not display adequate sensitivity to allow valid early diagnosis. Next-generation sequencing can be used to detect DNA markers down to the physical limit; however, this assay requires labeling and is time-consuming. The additional determination of a protein marker that is a predictor of aggressive behavior is a promising innovative approach, which holds the potential to improve diagnostic accuracy. Moreover, the possibility to detect biomarkers in blood serum offers the advantage of a noninvasive diagnosis. In this study, both the DNA and protein markers of pancreatic mucinous cysts were analyzed in human blood serum down to the single-molecule limit using the SiMoT (single-molecule assay with a large transistor) platform. The SiMoT device proposed herein, which exploits an inkjet-printed organic semiconductor on plastic foil, comprises an innovative 3D-printed sensing gate module, consisting of a truncated cone that protrudes from a plastic substrate and is compatible with standard ELISA wells. This 3D gate concept adds tremendous control over the biosensing system stability, along with minimal consumption of the capturing molecules and body fluid samples. The 3D sensing gate modules were extensively characterized from both a material and electrical perspective, successfully proving their suitability as detection interfaces for biosensing applications. KRAS and MUC1 target molecules were successfully analyzed in diluted human blood serum with the 3D sensing gate functionalized with b-KRAS and anti-MUC1, achieving a limit of detection of 10 zM and 40 zM, respectively. These limits of detection correspond to (1 ± 1) KRAS and (2 ± 1) MUC1 molecules in the 100 μL serum sample volume. This study provides a promising application of the 3D SiMoT platform, potentially facilitating the timely, noninvasive, and reliable identification of pancreatic cancer precursor cysts.Graphical abstract
<!>Introduction<!>Materials<!>Electrolyte-gated organic thin-film transistor fabrication<!><!>Gate biofunctionalization protocol<!>Sensing measurements<!>Results and discussion<!><!>Results and discussion<!><!>Results and discussion<!>Conclusions<!>
<p>Open access funding provided by Abo Akademi University (ABO).</p><!><p>The electronic detection of clinically relevant biomarkers with single-molecule limit of detection (LOD) represents a new frontline to advance the field of precision medicine [1]. Enhancing the analytical performance of bioelectronic systems, including the ability to detect clinically relevant markers at the physical limit, may completely change the way healthcare is delivered. Indeed, bioelectronic systems will enable clinicians to associate the smallest biomarker variations to the individual pathological condition, already at its initial phase. Ultimately, clinicians will be able to track the exact moment of the initiation of the disease state, enabling precise medical treatments (i.e., precision medicine), which will result in decreased healthcare-associated costs. Currently, the social burden of pancreatic cancer in Europe is about one million life-years annually [2], and by 2030 it will be the second leading cause of cancer-related death in the Western world [3]. Surgical resection in very early stages currently represents the only potentially curative treatment option; however, 80–90% of patients receive a diagnosis already in advanced stages and only palliative therapies can be offered [4]. Therefore, identification of high-risk individuals and markers for early detection represents a crucial step in changing the course of this disease. In this regard, an ultra-sensitive assay can enable a cancer risk assessment, identifying early-stage cancers and discriminating between benign and malignant forms [5]. Mucinous cysts of the pancreas are precursors of pancreatic cancer [6]. However, they belong to the large and heterogeneous spectrum of cystic lesions. Despite numerous international efforts and guidelines aimed at delivering reliable criteria for the distinction between harmless and potentially dangerous cystic lesions in the presurgical setting [7, 8], differential diagnosis remains challenging. Recently, a few studies have reported the analysis of multiple DNA markers by next-generation sequencing (NGS), increasing the accuracy of cystic fluid analysis in the diagnosis and subclassification of pancreatic cysts [9]. Although the NGS method is capable of sequencing of DNA markers, such as KRAS, GNAS and TP53, with a LOD of a single molecule (copy), it is time-consuming, requiring up to 1 week from clinical sampling to result. Additionally, it is based exclusively on genomic alterations, which give important information about the type of cysts (i.e. non-neoplastic vs. neoplastic), but are much less reliable concerning the biological behavior (i.e. low vs. high risk). The addition of a protein marker that is a predictor of aggressive behavior is a promising innovative approach, which has been rarely investigated so far [10]. For instance, MUC1 is a glycoprotein almost exclusively expressed by high-risk pancreatic cysts as well as in cells of pancreatic cancer itself [11]. Therefore, the availability of a system enabling the detection of MUC1 at a single-molecule level in the context of a multiparametric analysis approach (for instance the detection of both protein and DNA markers) has the potential to increase further the diagnostic accuracy of high-risk precursors of pancreatic cancer. However, ultrasensitive protein detection remains an extremely challenging task. Indeed, Simoa® technology can sense protein markers with attomolar (aM) LODs [12, 13], corresponding to 102−103 proteins in a sampled volume of 100 μL, being far less sensitive than NGS. Recently, Simoa Planar Array technology (SP-X System) [14] was developed based on a multiplex enzyme-linked immunosorbent assay (ELISA) system encompassing digital chemiluminescent imaging of an array of capture antibodies [15, 16]. Simoa SP-X technology can sense protein markers with LODs in the sub-femtomolar range. Moreover, Simoa and NGS are label-based, requiring laboratory facilities, and thus not at all suitable in point-of-care settings. Then, other relevant findings were accomplished, in which those technologies based on nanostructures seem to be the best candidates to consistently achieve label-free detection at the single-molecule level [17, 18]. They especially foresee the inspection of a femtoliter-sized volume in which the single-molecule under investigation is contained. The typical approach to single-molecule sensing, addressed as a near-field technique, entails a nanometer-sized detection interface. This implies a sensor component dimension comparable to that of the single-molecule to be detected, assuring a high signal-to-noise ratio [18].</p><p>Recently, the SiMoT (single-molecule assay with a large transistor) bioelectronic platform was successfully used for the detection of both proteins and DNA type markers, with a LOD at the single-molecule level [19–22]. This technology is based on an electrolyte-gated organic field-effect transistor (EG-OFET) [23], where a 0.5 cm2 gold gate electrode is biofunctionalized with ca. 1012 biorecognition elements, resulting in an extremely highly packed layer of capturing molecules. In this study, the SiMoT field-effect sensing system, involving a dual-gate structure, was fabricated by means of novel mass-producible, large-area-compatible, scalable techniques, including the inkjet printing of the organic semiconductor on plastic foil as well as the 3D printing of an innovative sensing gate module. By efficiently combining organic electronics and 3D printing processes, the 3D SiMoT platform was successfully used to assay KRAS and MUC1 mucinous lesions in blood serum samples with the same platform at the single-molecule detection limit. The platform is also single-use and cost-effective and can potentially work in low-resource settings. In particular, the 3D-printed sensing gate consists of a truncated cone that protrudes from a plastic substrate and is compatible with standard ELISA wells. The 3D gate is incubated in a standard ELISA plate containing the solutions involved in the biofunctionalization steps as well as in the human serum samples to be assayed. This approach provides a simple yet effective method for the biofunctionalization and incubation of the 3D gates with minimal consumption of the capturing molecules as well as body fluid samples. The amount of liquid for the biofunctionalization and incubation steps is the smallest possible, ensuring the cost-effectiveness of the biosensing system. Indeed, accounting for the nominal dimensions of both the ELISA plate well and the ad hoc design gate pillar, the maximum available volume is equal to 100 μL, while the minimum volume needed to enable the pillar top surface to touch the liquid is equal to 50 μL. Moreover, the design of the 3D SiMoT platform adds tremendous control over its stability, by combining a constant monitoring of the printed organic semiconductor operational stability in a water environment through the lateral reference gate and the fixed and optimized positioning of the 3D sensing gate. In addition, a protective layer of the connection tracks of the 3D sensing gate is designed in order to control the biofunctionalized gate area and to reduce spurious leakage currents as much as possible. Notably, a successful passivation strategy of tracks was proposed, leading to no contamination of the biofunctionalized gate area. The results gathered with the 3D SiMoT platform open the way for upscaling of the single biosensing device into an array structure manufactured using ultra-low-cost processes based on printed organic semiconductors and 3D printing, to obtain a multiplexing bioelectronic system. Moreover, the integration with the standard ELISA plates, used worldwide in clinical settings, can be foreseen, eventually delivering the fluids involved in the biofunctionalization and measurement phases by an automated procedure. Moreover, the lab-based device can be developed into a cost-effective portable prototype multiplexing array that integrates, with a modular approach, standard components and interfaces with novel materials, and it exhibits enhanced sensing capabilities for pancreatic cancer early diagnosis. Indeed, the 3D SiMoT will open the way for a massive use of high-throughput array-based assay not only in clinical laboratory analysis, but also in point-of-care and low-resource settings. The sensing platform is designed to be amenable for applications in several areas, and the final goal is to demonstrate that the detection of biomarkers at ultra-low levels holds the potential to enable new options for diagnostics and treatment of progressive diseases. The SiMoT platform endowed with a 3D gate component represents a very powerful technology to enable noninvasive early diagnosis of life-threatening progressive diseases. In particular, new diagnostic methods based on assay of the markers entirely in a peripheral fluid, with extremely low detection limits, should be of great relevance to replace the much more invasive procedures currently performed by means of biopsy. Such an analytical tool will indeed enable clinicians to associate the tiniest increase in a biomarker with the progression of a disease, particularly at its early stage. Eventually, the onset of the illness can be determined by physicians with higher accuracy. This will greatly enhance their ability to cure diseases by supporting better prognosis and permitting the application of precise treatment methods. An enormous improvement in the quality of life and longevity of the population for generations to come is foreseen along with a reduction in healthcare expenses.</p><!><p>Bovine serum albumin (BSA), high-performance liquid chromatography (HPLC)-grade water, high-grade ethanol (p.a. assay ≥ 99.8 %), streptavidin (SAV) from Streptomyces avidinii, phosphate-buffered saline (PBS) tablets, poly(3-hexylthiophene) (P3HT, high regioregularity ≥ 99%, average molecular weight [MW] of 20–45 kDa) were purchased from Sigma-Aldrich and used without any further purification. The device components, namely lateral gate and interdigitated source-drain electrodes, were printed on a 125 μm-thick poly(ethylene 2,6-naphthalate) (PEN) substrate, obtained from DuPont. The mucin 1 bioreceptor (anti-MUC1, clone UMAB57, code: UM800008) and the recombinant protein of human mucin 1, cell surface-associated (MUC1), transcript variant 2 (MUC1, MW = 25,100 Da, product number: TP321390) were provided by OriGene. 3-Mercaptopropionic acid (3-MPA), 11-mercaptoundecanoic acid (11-MUA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and the N-hydroxysulfosuccinimide sodium salt (Sulfo-NHS) were obtained from Merck Millipore (now MilliporeSigma). KRAS G12D (product number C9745(D07)) as target oligonucleotide, a biotinylated-KRAS G12D fwd (b-KRAS) (product number C9745(E03)) as biorecognition element and KRAS G12D 1MM (product number C9745(D12)) (one mismatch in correspondence of 14th nucleic acid base, used as negative control) were provided by Invitrogen-Thermo Fisher Scientific (oligonucleotides sequences are specified in previous reports) [10]. Human serum samples were obtained from blood samples collected from different healthy donor (age range 18–60 years, Research Donors Ltd of London [UK]) and diluted 1:4 with PBS and successively centrifuged at 10,000×g for 5 min, before the 3D SiMoT assay.</p><!><p>EG-OFETs with an inkjet-printed organic semiconductor were prepared on a flexible and PEN substrate as previously reported [24]. Afterwards, the samples were cleaned in acetone and 2-propanol (IPA) under ultrasonication, gently dried with a nitrogen flow and additionally cleaned for 2 min by means of oxygen plasma. S and D electrodes were photolithographically defined, possessing a 10.5 mm (width) × 5 μm (length) channel, while the circular lateral gate (LG) exhibited a radius of 1.25 mm. P3HT (2.6 mg/mL) was dissolved of in a mixture of chlorobenzene (CB) and o-dichlorobenzene (ODCB), 75:25 v/v, and inkjet-printed with a Fujifilm Dimatix DMP-2831. Details on the printed EG-OFET fabrication and operational stability in a water environment have been reported elsewhere [24].</p><!><p>(a) A schematic of the 3D SiMoT biosensing platform. (b) Micrograph of the transduction electronic channel encompassing the inkjet-printed P3HT deposited on top of the interdigitated source and drain electrodes along with the reference lateral gate. (c) Picture of the 3D-printed sensing gate, along with the "scotch test" highlighted in the red dashed box. (d) Side view of the 3D SiMoT sensor. (e) C1s (left) and Au4f (right) regions relevant to detection interface of the 3D sensing gate with Parylene-C passivation (red curves) and without passivation (blue curves) of the track</p><!><p>The 3D sensing gate modules were thoroughly washed using an ultrasonic bath in IPA for 10 min and subsequently rinsed with HPLC water, dried under N2 flux and then treated for 2 min in an ozone cleaner. The gate biofunctionalization protocol has been optimized and described in details elsewhere [23, 25]. Briefly, it undergoes the following steps: (i) 10 mM chemical self-assembled monolayer (chem-SAM) of 3-MPA to 11-MUA, with 10:1 molar ratio in ethanol for 18 h, (ii) chemical SAM (chem-SAM) activation with EDC (200 mM)/NHS (50 mM) for 2 h, (iii a) the single-strand bioprobe (oligonucleotide, b-KRAS) was immobilized through reaction with SAV (1.5 μM) for 2 h, deactivated with ethanolamine (1 M) and further reacted with biotinylated KRAS (0.5 μM) for 2 h, while for the anti-MUC1 (iii b) the 3D gate (with activated chem-SAM) was directly incubated with 0.4 mM (10 μg mL−1) of anti-MUC1, then deactivated with ethanolamine (1 M) and reacted with 1.5 μM (0.1 mg mL−1) BSA to prevent nonspecific binding. For anti-MUC1, the control experiment was performed by using a gate biofunctionalized only with BSA (0.1 mg mL−1). Moreover, for KRAS, KRAS G12D 1MM (one mismatch in correspondence of 14th nucleic acid base, used ass negative control) was used as control experiment. The whole biofunctionalization protocol was performed on a standard ELISA plate, using a volume of 100 μL of solution of each reagent. The gate biofunctionalization protocol was monitored through surface plasmon resonance (BioNavis multi-parameter surface plasmon resonance (MP-SPR) Navi™ 200) reproducing the biofunctionalization protocol on a glass slide coated with a 50 nm gold layer.</p><!><p>The 3D SiMoT device with an inkjet-printed organic semiconductor and lateral gate on plastic foil was stabilized before performing sensing experiments, according to the protocol defined and validated elsewhere [10, 24]. The sensing measurements were performed according to the following protocol. Each 3D sensing gate, for either DNA and protein assay, is washed thoroughly with HPLC water and mounted on top of the EG-OFET cell. A set of 20 transfer characteristics were recorded by sweeping the gate voltage VG from 0.1 V to −0.5 V and keeping fixed the drain voltage VD (−0.3 V) (each curve measured with a delay of 10 s). Next, the sensing gate was incubated for 10 min in 100 μl of human serum diluted 1:4. After the incubation, the functionalized 3D gate was thoroughly washed with HPLC water, and a new set of I–V transfer curves were registered. After I0 baseline measurement, the sensing gate was incubated in 100 μl of the human serum solutions spiked with standard aliquots of KRAS G12D rev or MUC1 ligands at concentrations ranging from 10 zM (1 × 10−20 M) to 1 fM (1 × 10−15 M) for 10 min. After incubation in each of the KRAS G12D rev or MUC1 sample, a further set of I–V transfer curves were measured, thus providing the signal I. The KRAS G12D rev and MUC1 standard solutions in diluted human blood serum were prepared by a serial dilution process according to the following equation: c2 = c1 · V1 / V2 =k · c1. Here, c1 and c2 are the ligand concentrations in the stock and in the diluted solution, respectively, while V1 and V2 are the corresponding solution volumes and k = V1 / V2 is the dilution factor. As is customary, the former dilution is the stock solution for the subsequent dilution in the series. Standard tenfold serial dilutions were performed starting from concentrated analyte mother solutions. The mother solutions have a concentration of 40 μM for the KRAS G12D target oligonucleotide and 100 nM for MUC1. The absolute uncertainty of the concentration for each standard solution was computed as the propagation error of the dilution factor, while the uncertainty of the volume, given by the supplier company of the pipettes used, is 1%. This value of the uncertainty of the volume considers both random and systematic errors in pipetting. The nominal number of MUC1 or KRAS (#Ligand) at each concentration is given by cVNA, where c is the ligand concentration, V is the volume of the standard PBS solution in which the gate is incubated (100 μL) and NA is the Avogadro number. Indeed, the 3D sensing gate was incubated into an aliquot of 100 μL of the ligand standard solution, as customary in single-molecule wide-field detection techniques [12, 26]. The error associated with the sampling procedure can be estimated according to the Poisson distribution. The total uncertainty of the ligand concentration was evaluated as the square root of the sum of the squares (RSS) of the dilution (σD) and Poisson (σP) errors. Therefore, the sensing gate was incubated in the human serum solutions hosting in 100 μl KRAS G12D rev or MUC1 ligands ranging from 1 ± 1 molecules (10 zM) to (6 104 ± 2 102) molecules (1 fM). In large-area (wide-field) transduction interfaces, a higher active area is exposed compared to near-field biosensing methods, thus proving to be a viable solution to overcome the diffusion barrier issue. This evidence is well supported by several experimental studies, mostly considering large-area interface field-effect transistors (FET) [27–29]. In addition, the latter exhibited LOD down to the attomolar level (aM, 10−18 M), with a response time shorter than hundreds of seconds. As demonstrated by several research groups [26], a single molecule in 100 μl (concentration of ~ 10–20 zM) undergoes diffusion and eventually impinging at millimeter-wide surface populated with trillions of recognition elements within a timescale of minutes. It was recently demonstrated how at least one out of a few molecules (< 10) diffusing in a large volume can impinge within 10 min on the large interface, generating a detectable signal at the LOD [30]. Importantly, the model also reveals that the fast spinning of the diffusing ligand enables us to quickly find the right orientation to bind to one capturing element independently of its orientation. Therefore, a FET bioelectronic sensor comprising a micrometric- or a millimetric-wide detection interface can perform single-molecule detection, being unaffected by diffusion-barrier issues, in contrast to nanometric interfaces. During each incubation step, the reference gate was monitored registering five transfer characteristics, each one with a delay of 10 s in the same voltage window utilized for the sensing gate. As negative control experiments, the following dose curves were registered for the (i) DNA and (ii) protein assays, respectively. The negative control experiments were designed, in the case of the DNA assay (i), with the dose curves involving the detection of KRAS with a single mismatch in the 14th base, against the same biotinylated probe attached to the gate, while for the protein assay, (ii) the dose curves involve the detection of MUC1 against a sensing gate biofunctionalized with BSA (0.1 mg mL−1). All the incubation steps were performed using a standard ELISA plate with incubation volume of 100 μL. Remarkably, a non-regenerative approach has been undertaken [31], due to the irreversible nature of the biorecognition element/ligand binding. Indeed, gold gate surface regeneration between consecutive analyte injections to remove the bound analytes cannot be used in case of stable ligand-analyte complexes, such as biorecognition element-analyte binding interactions involved in this study. In fact, with such systems the regeneration may fail in removing all the bound analyte molecules. As a result, the 3D SiMoT signal would not be close enough to the baseline after the regeneration. All data were plotted and analyzed with Origin2018.</p><!><p>The 3D SiMoT biosensing platform proposed in this study is outlined in Fig. 1. The device structure shown in Fig. 1a is based on the cost-effective EG-OFET, with inkjet-printed P3HT as channel material on top of the interdigitated source (S) and drain (D) electrodes, as shown in Fig. 1b.</p><!><p>Typical surface chemical composition of analyzed areas of 3D gates. Errors are determined on three replicates</p><p>(a) Pictorial view of the b-KRAS and anti-MUC1 bio-SAM layers attached to the chem-SAM. Surface plasmon resonance traces to quantify the immobilized b-KRAS (b) and anti-MUC1 (c). The SPR traces of the immobilization of the b-KRAS and anti-MUC1 on the Au surface are modified with the mixed alkanethiol chem-SAM</p><!><p>It is possible to compute the amount of b-KRAS and anti-MUC1 deposited per unit area from the layer thickness and the refractive index variation of non-homogeneous protein deposited on the sensor surface by using the de Feijter equation:1\documentclass[12pt]{minimal}
				sepackage{amsmath}
				sepackage{wasysym} 
				sepackage{amsfonts} 
				sepackage{amssymb} 
				sepackage{amsbsy}
				sepackage{mathrsfs}
				sepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				egin{document}$${\Gamma =rac{\left({n}_a-{n}_m
ight){d}_a}{rac{dn}{dc}}}$$\end{document}Γ=na-nmdadndcwhere na and nm are the average refractive index of the biolayer and the refractive index of the buffer solution, respectively, da is the average thickness of the biolayer, and dn/dc is the specific refractivity associated to the biolayer. By including the instrument signal in Eq. (1), the following equation holds true:2\documentclass[12pt]{minimal}
				sepackage{amsmath}
				sepackage{wasysym} 
				sepackage{amsfonts} 
				sepackage{amssymb} 
				sepackage{amsbsy}
				sepackage{mathrsfs}
				sepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				egin{document}$$\left({n}_a-{n}_m
ight)=arDelta 	heta st k$$\end{document}na-nm=Δθ*kwhere k is a coefficient for sensitivity (wavelength-dependent), and Δθ is the measured angular response (angle shift) in the measurement. Therefore, Eq. (1) becomes3\documentclass[12pt]{minimal}
				sepackage{amsmath}
				sepackage{wasysym} 
				sepackage{amsfonts} 
				sepackage{amssymb} 
				sepackage{amsbsy}
				sepackage{mathrsfs}
				sepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				egin{document}$$\Gamma =rac{\Delta 	heta st kst {d}_a}{rac{dn}{dc}}$$\end{document}Γ=Δθ*k*dadndc</p><p>For a thin layer (100 nm maximum thickness), the product k*da can be approximated to be constant and equal to 1.0 × 10−7 cm/deg for the laser wavelength used in this study (λ = 670 nm). Following the literature, the dn/dc value can be approximated to 0.182 cm3/g at 670 nm [38], leading to the calculation of biomolecule surface coverage as4\documentclass[12pt]{minimal}
				sepackage{amsmath}
				sepackage{wasysym} 
				sepackage{amsfonts} 
				sepackage{amssymb} 
				sepackage{amsbsy}
				sepackage{mathrsfs}
				sepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				egin{document}$$\Gamma =\Delta 	heta st 550\ ng/{cm}^2$$\end{document}Γ=Δθ*550ng/cm2</p><p>Upon injection of 100 μL of a 0.5 μM b-KRAS buffer solution, an angular shift is registered, as seen in Fig. 2b. Using Eq. (4), the resulting surface coverage Γ = 52.7 ± 0.1 ng/cm2 is calculated at equilibrium after removing the b-KRAS excess. By considering the molecular weight of a single b-KRAS strand, the average number of active binding sites available is estimated at about (4.01 ± 0.01) × 1012 molecules/cm2. Similarly, when 10 μg mL−1 of anti-MUC1 buffer solution is injected, the resulting surface coverage is equal to Γ = 52 ± 1 ng/cm2, corresponding to an estimated average total number of binding sites effectively available of (2.10 ± 0.05) × 1011 molecules/cm2. This is a very densely packed recognition layer, as customary for a SiMoT device. Moreover, the covalent approach used herein in the anti-MUC1 immobilization onto the gate surface modified with the chem-SAM occurs via available functional groups of exposed amino acids. Remarkably, protein exhibits random orientation upon covalent binding due to the immobilization through –NH2 groups available at several amino acid residues (e.g., lysine), resulting in a heterogeneous and non-oriented biofilm. However, the SPR surface characterization, demonstrating the availability of ~1012 bioactive capturing anti-MUC1, along with the SAM surface characterization [23] strongly suggests that the anti-MUC1 packed in the SAM largely lay edge-on with one of their Fab fragments pointing away from the gate surface. Therefore, the resulting layer is probably characterized by a certain degree of order [39]. Moreover, it is reported that, at physiological pH, antibodies bear a dipole moment oriented from the Fc to the Fab region, and thus the overall weakly oriented dipoles are likely to provide the bio-SAM with electrostatic properties. Such evidence can also possibly add a weak electrostatic driving force component to the affinity binding process.</p><!><p>Stable transfer characteristics (ID vs. VG at fixed VD = −0.3V) upon exposure to diluted human blood serum, as the baseline signal, and further exposed to human blood serum spiked with (a) KRAS and (b) MUC1 with concentrations ranging from 10 zM to 1 fM. (c) KRAS/b-KRAS dose–response curve (hollow red squares) are presented as the ΔI/I0 vs. KRAS concentration. The negative control experiment towards KRAS with one mismatch is reported as hollow black squares. (d) MUC1/anti-MUC1 dose–response curve (hollow red squares) are presented as the ΔI/I0 vs. MUC1 concentration. A BSA biofunctionalized gate was employed in the control experiment (hollow black squares). All the data points are provided as the average of at least three replicates, while the error bars were computed as the relative standard deviation, providing an estimation of the reproducibility of the assay</p><!><p>According to the IUPAC definition, the LOD was estimated as the concentration corresponding to a response equal to (ΔI/I0)mean
± kσ, where (ΔI/I0)mean is the average response of the negative control experiment, while σ is its standard deviation and k is selected depending on the requested confidence level [41]. IUPAC recommends to select k equal to 3, resulting in the probability of a negative control signal being threefold higher than the (ΔI/I0)mean (i.e. a false positive being less than 1%). Considering the noise level and the standard deviation of the control experiments of each assay, LOD levels of −4% and −10 % were estimated for KRAS and MUC1 assays, respectively. Therefore, the LOD computed for the KRAS assay is equal to 10 zM, corresponding to 1 ± 1 molecule in the 100 μL sampled volume. Moreover, the LOD level matches to MUC1 nominal concentration of 40 zM, corresponding to 2 ± 1 molecules in the 100 μL sampled volume. As it is apparent all the assays, in diluted blood serum, detect at the physical limit both proteins and DNA markers using the same 3D SiMoT platform.</p><p>Remarkably, the sigmoid exponential dependence from the analyte concentration reported in Fig. 3c and d suggests a binary response, capable of assessing the total absence or the presence of just a single molecule of a marker of a progressive disease in the sampled biofluid. The amplification mechanism at the basis of the ultra-high sensitivity of the 3D SiMoT platform might be enabled by a built-in mechanism that switches the gate biolayer work function, measured as a shift of the SiMoT threshold voltage (VT). Such a mechanism has been postulated and is described in detail elsewhere and briefly recalled [22, 23]. The amplification mechanism is assumed to rely on an electrostatic network of dipoles (hydrogen bonding) connecting the packed molecules of the biolayer. Operating the device in the gate field orients these dipoles, while the binding event triggers a conformational change that generates a defect, changing the local dipole arrangement (work function) that propagates in the gating field, amplifying the single-binding signal. The main features of this biolayer amplification effect is that an up to 30% relative output current change compared to the background signal is registered when only few analyte molecules are in the biofluid solution, while the background noise, evaluated on a negative control experiment, is only within 5% of the relative standard deviation. Therefore, this platform might be of enormous importance in supporting clinicians to sort an asymptomatic population into those who have been tested with at least one marker, likely to be diseased, from those who have no marker, likely to be healthy.</p><!><p>In conclusion, in this study the design, fabrication process flow and the development of a 3D SiMoT biosensing system have been reported. Remarkably, the 3D SiMoT device has been proven capable of detecting at the single-molecule level both KRAS and MUC1 markers in human blood serum. The validation of the 3D-printed sensing gate module was carried out by measuring the transfer characteristic curves of an EG-OFET device comprising an inkjet-printed organic semiconductor and a lateral gate on plastic foil. In particular, the adopted 3D printing technology and the design flow for the realization of the sensing gates were optimized, enabling minimization of the volume of biofluids used for the biofunctionalization of the gate electrodes as well as for the assays, while maintaining full compatibility with the standard ELISA plate. The 3D sensing gate modules were extensively characterized from both a material and electrical perspective, successfully demonstrating their suitability as detection interfaces for ultra-stable biosensing applications. KRAS and MUC1 target molecules were successfully assayed in diluted human blood serum with the 3D sensing gate functionalized with b-KRAS and anti-MUC1, achieving a LOD of 10 zM and 40 zM, respectively. Those limits of detection correspond to 1 ± 1 molecules of KRAS and 2 ± 1 molecules of MUC1 in 100 μL sample volume of human blood serum. By efficiently combining organic electronics and 3D printing processes, the 3D SiMoT field-effect sensing system adds tremendous control over the biosensor stability, representing an exceptionally compelling technology to enable noninvasive and cost-effective early diagnosis of life-threatening progressive diseases. As a future perspective, the 3D SiMoT technology might also be expanded into a fully printed electronic array, capable of multiplexing of several biomarkers directly into a peripheral body fluid, such as blood. This could open the door to widespread practice of liquid biopsy for the early diagnosis of high-grade pancreatic mucinous cysts, supporting and possibly improving existing diagnostic practices.</p><!><p>Publisher's note</p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>